Sold as Kayexalate. Every FDA application for this active ingredient: 1 branded and 17 generic.
As of Nov 15, 2026, FDA lists 18 applications for Sodium Polystyrene Sulfonate (sold as Kayexalate), first approved Jun 5, 1958, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Sodium Polystyrene Sulfonate | Part D | $3.0M | +1% | 30,517 |
| OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart FailureHeart Failure, Hyperkalemia · Michael Fu | Phase 2 | Active, not recruiting | Mar 9, 2021 |
| Osseointegration of THA Grafted by PolyNASS (ACTISURF-CERAFIT® ) Versus Non-grafted THA (CERAFIT®)Osteoarthritis, Hip, Coxarthrosis; Primary · Societe ACTIVBIOMAT | Not applicable | Active, not recruiting | Apr 14, 2017 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Hikma
Roxane